Company intelligence / Profile preview

TRexBio

South San Francisco, California, United Statestrex.bio ↗

Ownership: Private
Employees: ~100
Development stage: Phase 1

Overview

TRexBio is advancing its lead program TRB-061 to clinical trials in early 2025. The company is developing therapeutics that modulate the immune system to restore tissue immune homeostasis[3].

Therapeutic areas: Immunology
Industry: Biotech

Drug pipeline

5 assets

TRB-061

4 more assets in the full pipeline.

Partnerships

Johnson & Johnson (for a preclinical program)[3]Eli Lilly (as part of Lilly Gateway Labs)[3]

Beyond the preview

Go deeper on TRexBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRexBio.